[go: up one dir, main page]

WO2009093251A3 - Reovirus vaccine based on sigma c protein sequence - Google Patents

Reovirus vaccine based on sigma c protein sequence Download PDF

Info

Publication number
WO2009093251A3
WO2009093251A3 PCT/IL2009/000098 IL2009000098W WO2009093251A3 WO 2009093251 A3 WO2009093251 A3 WO 2009093251A3 IL 2009000098 W IL2009000098 W IL 2009000098W WO 2009093251 A3 WO2009093251 A3 WO 2009093251A3
Authority
WO
WIPO (PCT)
Prior art keywords
sigma
protein sequence
vaccine based
peptide
reovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2009/000098
Other languages
French (fr)
Other versions
WO2009093251A2 (en
Inventor
Jacob Pitcovski
Dana Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gavish-Galilee Bio Applications Ltd
Original Assignee
Gavish-Galilee Bio Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gavish-Galilee Bio Applications Ltd filed Critical Gavish-Galilee Bio Applications Ltd
Publication of WO2009093251A2 publication Critical patent/WO2009093251A2/en
Publication of WO2009093251A3 publication Critical patent/WO2009093251A3/en
Anticipated expiration legal-status Critical
Priority to IL207196A priority Critical patent/IL207196A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A peptide selected from a peptide derived from a conserved region of a sigma C protein of an avian reovirus isolate, and an analog of said peptide are provided, as well as broad activity anti-reovirus vaccines comprising said peptide.
PCT/IL2009/000098 2008-01-24 2009-01-25 Reovirus vaccine based on sigma c protein sequence Ceased WO2009093251A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL207196A IL207196A0 (en) 2008-01-24 2010-07-25 Reovirus vaccine based on sigma c protein sequence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2314608P 2008-01-24 2008-01-24
US61/023,146 2008-01-24

Publications (2)

Publication Number Publication Date
WO2009093251A2 WO2009093251A2 (en) 2009-07-30
WO2009093251A3 true WO2009093251A3 (en) 2009-10-22

Family

ID=40848562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000098 Ceased WO2009093251A2 (en) 2008-01-24 2009-01-25 Reovirus vaccine based on sigma c protein sequence

Country Status (1)

Country Link
WO (1) WO2009093251A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968671B2 (en) 2014-01-29 2018-05-15 University Of Georgia Research Foundation, Inc. Avian reovirus vaccines

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101600959B1 (en) * 2013-06-18 2016-03-08 단국대학교 산학협력단 Recombinant Protein Comprising Epitope of Avian reovirus sigma C Protein and Antibody thereto
HUE063529T2 (en) * 2014-10-03 2024-01-28 Intervet Int Bv Broad-spectrum vaccine against avian reovirus
CA3009289A1 (en) * 2016-01-07 2017-07-13 Gavish-Galilee Bio Applications Ltd Optimized polypeptide for a subunit vaccine against avian reovirus
CN116120468B (en) * 2023-03-16 2023-09-08 扬州优邦生物药品有限公司 Virus-like particle vaccine for preventing avian reovirus and preparation method thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
WO2000037487A1 (en) * 1998-12-19 2000-06-29 Merck Patent Gmbh αvβ6 INTEGRIN INHIBITORS
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
WO2001096377A2 (en) * 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
WO2004031211A2 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
WO2005110456A2 (en) * 2004-05-11 2005-11-24 Abgenomics Corporation T-cell death-inducing epitopes
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
WO2000037487A1 (en) * 1998-12-19 2000-06-29 Merck Patent Gmbh αvβ6 INTEGRIN INHIBITORS
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001096377A2 (en) * 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
WO2004031211A2 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
WO2005110456A2 (en) * 2004-05-11 2005-11-24 Abgenomics Corporation T-cell death-inducing epitopes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU CHIEN J ET AL: "Development and characterization of monoclonal antibodies against avian reovirus .sigma.C protein and their application in detection of avian reovirus isolates", AVIAN PATHOLOGY, HUNTINGDON, CAMBS, GB, vol. 35, no. 4, 1 August 2006 (2006-08-01), pages 320 - 326, XP008107192, ISSN: 0307-9457 *
VASSERMAN Y ET AL: "The influence of reovirus sigma C protein diversity on vaccination efficiency", AVIAN DISEASES, AMERICAN ASSOCIATION OF AVIAN PATHOLOGISTS, KENNET SQ., PA, US, vol. 48, no. 2, 1 April 2004 (2004-04-01), pages 271 - 278, XP008107191, ISSN: 0005-2086 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968671B2 (en) 2014-01-29 2018-05-15 University Of Georgia Research Foundation, Inc. Avian reovirus vaccines
US10588958B2 (en) 2014-01-29 2020-03-17 University of Georgia Research Foundations, Inc. Avian reovirus vaccines
US11090377B2 (en) 2014-01-29 2021-08-17 University Of Georgia Research Foundation, Inc. Avian reovirus vaccines

Also Published As

Publication number Publication date
WO2009093251A2 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
WO2012024632A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e
WO2010065815A3 (en) Mini-hepcidin peptides and methods of using thereof
WO2010006144A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2014052378A3 (en) Subunit immersion vaccines for fish
EP2029167A4 (en) Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
WO2011022667A3 (en) Catalytic domains from lysyl oxidase and loxl2
WO2012168430A3 (en) Polypeptides
IN2012DN03928A (en)
WO2004080403A3 (en) Influenza virus vaccine
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
WO2008021959A3 (en) Influenza hemagglutinin and neuraminidase variants
NZ597401A (en) Chimeric influenza virus-like particles comprising hemagglutinin
IL212787A0 (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2011022656A3 (en) Recombinant avian paramyxovirus vaccine and method for making and using thereof
BRPI0913216A2 (en) use of a recombinant herpesvirus of turkeys, and recombinant herpesvirus of turkeys.
WO2006098901A3 (en) Influenza hemagglutinin and neuraminidase variants
WO2011106493A3 (en) Oral care compositions comprising magnolia bark extract or a synthetic analog thereof
WO2009093251A3 (en) Reovirus vaccine based on sigma c protein sequence
EP2684950A4 (en) Pegylated analogue protein of canine urate oxidase, preparation method and use thereof
WO2006115843A3 (en) Nipah virus vaccines
IL200588A0 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
EP3111924A3 (en) Oral care compositions
WO2014140166A3 (en) Vaccine
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
EP2610349A4 (en) Whole egg protein peptides, preparation method and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 207196

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09703950

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09703950

Country of ref document: EP

Kind code of ref document: A2